Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders.

Journal: Influenza and other respiratory viruses

Volume: 18

Issue: 3

Year of Publication: 2024

Affiliated Institutions:  Westat, Rockville, Maryland, USA. HealthPartners Institute, Minneapolis, Minnesota, USA. Kaiser Permanente Center for Health Research, Portland, Oregon, USA. Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA. Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Baylor Scott & White Health, Temple, Texas, USA. Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA. School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA. Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA. Children's Minnesota, Minneapolis, Minnesota, USA. Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Abstract summary 

Although psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID-19 vaccine effectiveness (VE). This study evaluated risk of COVID-19 hospitalization and estimated mRNA VE stratified by psychiatric disorder status.In a retrospective cohort analysis of the VISION Network in four US states, the rate of laboratory-confirmed COVID-19-associated hospitalization between December 2021 and August 2022 was compared across psychiatric diagnoses and by monovalent mRNA COVID-19 vaccination status using Cox proportional hazards regression.Among 2,436,999 adults, 22.1% had ≥1 psychiatric disorder. The incidence of COVID-19-associated hospitalization was higher among patients with any versus no psychiatric disorder (394 vs. 156 per 100,000 person-years, p < 0.001). Any psychiatric disorder (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.18-1.37) and mood (aHR, 1.25; 95% CI, 1.15-1.36), anxiety (aHR, 1.33, 95% CI, 1.22-1.45), and psychotic (aHR, 1.41; 95% CI, 1.14-1.74) disorders were each significant independent predictors of hospitalization. Among patients with any psychiatric disorder, aHRs for the association between vaccination and hospitalization were 0.35 (95% CI, 0.25-0.49) after a recent second dose, 0.08 (95% CI, 0.06-0.11) after a recent third dose, and 0.33 (95% CI, 0.17-0.66) after a recent fourth dose, compared to unvaccinated patients. Corresponding VE estimates were 65%, 92%, and 67%, respectively, and were similar among patients with no psychiatric disorder (68%, 92%, and 79%).Psychiatric disorders were associated with increased risk of COVID-19-associated hospitalization. However, mRNA vaccination provided similar protection regardless of psychiatric disorder status, highlighting its benefit for individuals with psychiatric disorders.

Authors & Co-authors:  Levy Yang Dunne Miley Irving Grannis Weber Griggs Spark Bassett Embi Gaglani Natarajan Valvi Ong Naleway Stenehjem Klein Link-Gelles DeSilva Kharbanda Raiyani Beaton Dixon Rao Dascomb Patel Mamawala Han Fadel Barron Grisel Dickerson Liao Arndorfer Najdowski Murthy Ray Tenforde Ball

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Yang H., Chen W., Hu Y., et al., “Pre‐Pandemic Psychiatric Disorders and Risk of COVID‐19: A UK Biobank Cohort Analysis,” Lancet Healthy Longev 1 (2020): e69–e79.
Authors :  40
Identifiers
Doi : e13269
SSN : 1750-2659
Study Population
Male,Female
Mesh Terms
Adult
Other Terms
COVID-19;anxiety disorders;electronic health records;epidemiology;mental disorders;mood disorders;psychotic disorders;vaccination
Study Design
Study Approach
Country of Study
Publication Country
England